Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-GATA3 gene therapy - Sterna Biologicals

Drug Profile

Anti-GATA3 gene therapy - Sterna Biologicals

Alternative Names: hgd40; SB-010; SB-011; SB-012

Latest Information Update: 22 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sterna biologicals; University of Marburg
  • Developer German Center for Lung Research; sterna biologicals
  • Class Anti-inflammatories; Antiasthmatics; Antisense oligonucleotides; Catalytic DNA; Skin disorder therapies
  • Mechanism of Action GATA3 transcription factor inhibitors; RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Ulcerative colitis

Highest Development Phases

  • Phase II Allergic asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Ulcerative colitis

Most Recent Events

  • 22 Nov 2022 Anti-GATA3 gene therapy - Sterna Biologicals is available for licensing as of 22 Nov 2022. https://www.sterna-biologicals.com/pipeline
  • 14 Dec 2021 Sterna Biologicals initiates enrolment in the phase IIa GIANT-1 trial in Asthma in Germany (Inhalation) (Sterna Biologicals pipeline, January 2022)
  • 07 Jan 2021 Sterna Biologicals plans a phase I/IIb with SB 012 in Ulcerative colitis in the first half of 2023 (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top